Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (285) clinical trials

Efficacy of Adjuvant Mitotane Treatment (ADIUVO)

Endpoints Primary : To compare DFS (Disease Free Survival), defined as the time between the date of randomization until documentation of any of the following failures (whichever occurs first): -local or distant recurrence of disease;-death from any cause or completion of follow-up. Secondary: To compare OS (Overall Survival), defined as ...

Phase

Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors

Until now, in trials it is common to stop therapy when progressive disease occurs; RECIST criteria are used, in which progressive disease is defined as >20% increase of the sum of the longest diameter of the lesions, or occurence of new lesions. However, angiogenesis inhibitors have a rather cytostatic than ...

Phase

Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients

The study is designed as a Phase II, prospective, non randomized, open-label, single arm, multicenter trial, in which patients with locally advanced or metastatic ACC not amenable to complete surgical resection. STUDY OBJECTIVES The aim of this phase II trial is to evaluate the clinical benefit and toxicity of the ...

Phase

Epirubicin Oxaliplatin and Capecitabine or Docetaxel and Oxaliplatin in Treating Patients With Advanced Esophageal Cancer Gastroesophageal Junction Cancer or Stomach Cancer

OBJECTIVES: Primary - Compare the response rate in patients with advanced esophageal, gastroesophageal junction, or gastric cancer treated with epirubicin hydrochloride, oxaliplatin, and capecitabine vs docetaxel and oxaliplatin. Secondary - Compare the time to progression, survival, and quality of life of patients treated with these regimens. - Compare the toxicities ...

Phase

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

Radiation therapy is an effective and frequently utilized modality for the treatment of clinically localized prostate cancer. Traditionally, external beam radiation has been delivered in a fractionated manner using daily doses of 1.8-2.0 Gy. This daily dose was derived from early animal experiments and clinical experience, supported by mathematical models ...

Phase

Use of Tracking Devices to Locate Abnormalities During Invasive Procedures

Background: The effectiveness of targeting lesions or a specific area for surgery, angiography, CT-guided, or ultrasound-guided biopsy, or ablation, currently may be limited by the visibility of a target during the procedure. Accurate therapeutic intervention may depend upon accurate device placement, which may be very difficult in certain settings, such ...

Phase N/A

Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

Patients with relapsing and/or metastatic adenoid cystic carcinoma of the salivary gland of the head and neck are usually poor responders to conventional cytotoxic chemotherapy. The investigation of proliferation pathways involving tyrosine kinase receptors such as c-kit receptor (KIT) and PDGF receptor may allow to identify a molecular target for ...

Phase

Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody Yttrium-90 Conjugated Chimeric G250

This is a Phase I dose escalation study using 90Y-DOTA-cG250 for treatment of patients with advanced kidney carcinoma. The initial group of patients will be treated with 0.2 mCi/Kg of yttrium-90. Subsequent treatments will be in 0.1 mCi/Kg increments, with the last cohort increasing by 0.05 mCi/Kg. At least three ...

Phase

Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer

Approximately 75% of all patients with colon carcinoma present at a stage when all gross tumor can be surgically resected. Despite that high resectability rate, about 50% of all colon adenocarcinoma patients die of subsequent metastatic disease not apparent at surgery. These individuals could benefit from adjuvant local or systemic ...

Phase

Immunochemotherapy for Metastatic Renal Cell Carcinoma

This is a phase II study, non-randomized in patients with metastatic renal cell carcinoma. The treatment will include: Proleukin (produced by Chiron and supplied by Megapharm Israel Ltd), Roferon A and Xeloda (produced by Roche) and VBL. The treatment will be given in 8-week courses with an interval of two ...

Phase